Stockscreener 앱 받기
127.04
0.58%
-0.74
시간 외 거래:
127.05
0.010
+0.01%
전일 마감가:
$127.78
열려 있는:
$128.45
하루 거래량:
6.62M
Relative Volume:
1.08
시가총액:
$220.91B
수익:
$43.84B
순이익/손실:
$13.90B
주가수익비율:
15.93
EPS:
7.9725
순현금흐름:
$6.92B
1주 성능:
+1.40%
1개월 성능:
+1.57%
6개월 성능:
-4.98%
1년 성능:
+12.03%
1일 변동 폭
$126.27
$128.60
1주일 범위
$122.50
$129.46
52주 변동 폭
$110.86
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
127.04 | 222.19B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.65 | 144.97B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.75 | 140.12B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.77 | 128.60B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.83 | 49.82B | 5.88B | 1.34B | 799.60M | 2.3489 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Steady Multi‑Year Returns - simplywall.st
17-year Abbott employee sues, alleges firing over approved FMLA use - HRD America
Abbott: Not Cheap, But Built To Compound In Uncertain Markets (NYSE:ABT) - Seeking Alpha
Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy - The Globe and Mail
Abbott’s $105 Bid Put Exact Sciences Back In Play - Finimize
Abbott’s New Libre Assist AI Tool Might Change The Case For Investing In Abbott Laboratories (ABT) - simplywall.st
Abbott Laboratories (NYSE:ABT) Given New $144.00 Price Target at Evercore ISI - MarketBeat
Should Abbott’s AI-Powered Libre Assist Shift Its Diabetes Platform Strategy Narrative for ABT Investors? - Yahoo Finance
Hematology Market Booming with Rapid Growth Through 2033 | - openPR.com
Abbott Laboratories $ABT Shares Sold by Commonwealth Equity Services LLC - MarketBeat
Abbott (ABT) Rises Higher Than Market: Key Facts - Yahoo Finance
Abbott unveils new FreeStyle Libre app feature for mealtime decisions - MassDevice
How to listen as Abbott breaks down its latest quarterly results Jan. 22 - Stock Titan
In wake of Minnesota fraud, Abbott directs investigation into childcare programs - TPI Media Group
Abbott Laboratories Stock Gains Momentum from AI and Analyst Confidence - AD HOC NEWS
Abbott Laboratories (NYSE:ABT) Price Target Raised to $169.00 - MarketBeat
Railway Pension Investments Ltd Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Healthcare Weight In S&P 500 Chart - Kalkine Media
Synergy Asset Management LLC Sells 40,094 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Acquired by Asset Management One Co. Ltd. - MarketBeat
2 Healthcare Stocks to Buy in a Bear Market - The Globe and Mail
JARISLOWSKY FRASER Ltd Has $289.05 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Has A Rock Solid Balance Sheet - 富途牛牛
Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT) - simplywall.st
Tectonic Advisors LLC Decreases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
The Truth About Abbott Laboratories: Is This ‘Boring’ Stock Actually a Secret Power Play? - AD HOC NEWS
Top 2 Health Care Stocks That May Crash In Q1 - Benzinga
Allspring Global Investments Holdings LLC Acquires 69,578 Shares of Abbott Laboratories $ABT - MarketBeat
Bank Pictet & Cie Europe AG Has $9.82 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature - FinancialContent
Ninety One SA PTY Ltd Takes $1.49 Million Position in Abbott Laboratories $ABT - MarketBeat
Mather Group LLC. Raises Position in Abbott Laboratories $ABT - MarketBeat
Merit Financial Group LLC Acquires 20,035 Shares of Abbott Laboratories $ABT - MarketBeat
With EPS Growth And More, Abbott Laboratories (NYSE:ABT) Makes An Interesting Case - Yahoo Finance
Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings? - TradingView — Track All Markets
The Truth About Abbott Laboratories: Viral Hype Or Boring Boomer Stock You’re Sleeping On? - AD HOC NEWS
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance
Shum Financial Group Inc. Acquires Shares of 8,127 Abbott Laboratories $ABT - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 245,400 Shares of Abbott Laboratories $ABT - MarketBeat
Brendel Financial Advisors LLC Sells 23,978 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus - ts2.tech
Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment - Finviz
Traders Buy Large Volume of Call Options on Abbott Laboratories (NYSE:ABT) - MarketBeat
Exact Sciences Approves Executive Bonus Acceleration Amid Abbott Merger - The Globe and Mail
Oak Harvest Investment Services Decreases Stake in Abbott Laboratories $ABT - MarketBeat
Diversified Trust Co Boosts Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Walks a Tightrope Between Defensive Haven and Growth Re?Rating - AD HOC NEWS
Abbott Laboratories (NYSE:ABT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
U.S. Embolic Protection Devices Market and Competition - GlobeNewswire
U.S. Embolic Protection Devices Market and Competition Analysis, 2025-2033, Featuring Abbott Laboratories, Allium Medical Solutions, Boston Scientific, Cardinal Health and More - Yahoo Finance
Ethic Inc. Has $29.96 Million Position in Abbott Laboratories $ABT - MarketBeat
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.88%
0.54%
자본화:
|
볼륨(24시간):